Please login to the form below
Regeneron
This page shows the latest Regeneron news and features for those working in and with pharma, biotech and healthcare.
Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease
Sanofi and Regeneron have shared positive results from a late-stage trial of Dupixent (dupilumab) in chronic obstructive pulmonary disease (COPD). ... Sanofi and Regeneron outlined that they plan to submit the data from NOTUS, along with positive results
Latest news
-
Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their existing research collaboration to develop additional CRISPR-based gene editing therapies for neurological and muscular diseases. ... Intellia will lead the design of the editing
-
Regeneron’s odronextamab granted FDA priority review for non-Hodgkin lymphoma
Regeneron’s odronextamab is designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. ... Regeneron also outlined that it is initiating a “broad phase 3 development programme”
-
Alnylam's patisiran backed by FDA advisory committee for ATTR cardiomyopathy
In July, Alnylam presented positive results for its Regeneron-partnered gene silencing RNAi therapeutic in early-onset Alzheimer’s disease.
-
US government awards $1.4bn for development of COVID-19 vaccines and therapeutics
The funding includes a contract with Regeneron for a next-generation antibody therapy. ... Regeneron previously developed a monoclonal antibody therapy against COVID-19, REGEN-COV, which was authorised by the US Food and Drug Administration in November
-
Regeneron's Veopoz granted FDA approval for ultra-rare immune disease
Regeneron Pharmaceuticals’ Veopoz (pozelimab-bbfg) has been approved by the US Food and Drug Administration (FDA) to treat patients with an ultra-rare immune disease. ... George Yancopoulos, Regeneron’s president and chief scientific officer, said:
More from news
Approximately 120 fully matching, plus 198 partially matching documents found.
Latest Intelligence
-
COVID-19: the race to find a vaccine
The same approach may work against SARSCoV-2. Regeneron Pharmaceuticals, leveraging a platform that spawned an Ebola treatment, is leading efforts to show that antibodies can neutralise SARS-CoV-2. ... A clinical trial of Regeneron’s drug is scheduled
-
As COVID-19 takes over the world, biopharma fights back
Evaluating IL-6 inhibitors: Roche’s Actemra and Sanofi and Regeneron’s Kevzara. Roche, Sanofi and Regeneron are also looking to repurpose their existing treatments and are currently testing their ... 19,” said George D Yancopoulos, co-founder,
-
20 for 2020 – Five pharma leaders to watch in 2020
The changes also mean Sanofi has downgraded some long-standing relationship in R&D – such as a fruitful tie-up with Regeneron that generated some of its top-selling drugs like ... Analysts think the deal could catapult Galapagos into the top tier of
-
Case study: See Below
Client:Sanofi Genzyme and Regeneron. Agency:Havas Lynx Group. Campaign:See Below. Timescale:N/A. Atopic dermatitis affects approximately 1-3% of adults worldwide. ... Topical corticosteroids are commonly used to treat atopic dermatitis. Sanofi Genzyme
-
Innovation and digital health comms recognised at Communiqué Awards
Innovation in Healthcare Communications. One high profile winning campaign was Havas Lynx Group’s ‘See Below’ on behalf of Sanofi Genzyme and Regeneron.
More from intelligence
Approximately 1 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Tiziana Life Sciences appoints clinical sciences VP
Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson &Johnson and Regeneron.
-
Regeneron taps Pfizer for CFO
Robert Landry succeeds Murray Goldberg. Former Pfizer senior VP Robert Landry has joined Regeneron as senior VP, finance, and will later take over as chief financial officer. ... We are extremely fortunate that Murray will stay at Regeneron through 2014
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
Sandra Graham-Mason, Director of Marketing at Regeneron Pharmaceuticals discusses a variety of topics, from the impact of COVID-19 on the way that Pharma teams interact with internal stakeholders and
-
COUCH Health
Shire/Takeda. Pfizer. Amgen. Regeneron.
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Twist Health
Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
